RE:Dream.PMN310 is still the dream, as it was when Giovinazzo came on board. Cracking that market is a huge lift, and doing R&D in some of these other areas while the PMN310 business plan matures is time well spent. This company has a capability, not just a one-off product.
PMN310 clinical entry has been admittedly behind schedule.
But the bottom line is that aducanumab and BAN2401 leave a lot on the table in terms of opportunity for improvement, and PMN310 offers the next gen solution that technically appears to be a better option. It has higher affinity and specificity, and there is a clear dose response effect in the aducanumab data.
If I were Biogen and seeking FDA approval, there is no way I would make a deal for developing a better version of aducanumab before aducanumab gets approved. That would basically say to to the FDA- 'aducanumab isn't good enough, and there may be a safer option out there in a few years'. I think that would complicate the FDA approval process. They need to appear to be the only option out there for the foreseeable future.